Literature DB >> 9142777

Cytomegalovirus disease occurring before engraftment in marrow transplant recipients.

A P Limaye1, R A Bowden, D Myerson, M Boeckh.   

Abstract

Little information is available regarding the incidence, clinical course, and response to treatment of cytomegalovirus (CMV) disease that occurs before engraftment in marrow transplant recipients. We identified 25 patients over a 12.5 year period who developed CMV disease before achieving engraftment. Twelve cases were diagnosed during life, and 13 cases were diagnosed at autopsy. The lung was the site most commonly involved (92% of patients), and most of the patients (92%) were CMV seropositive. Significant copathogens were identified in 45% of the patients. All nine patients with CMV pneumonia died within 6 weeks after the diagnosis was made, and one of two patients with gastrointestinal disease also died 6 weeks after the diagnosis was made despite the administration of antiviral therapy. Surveillance cultures were not helpful in identifying patients at risk for disease. Histopathological examination of the lungs of patients with early CMV pneumonia only infrequently showed typical CMV lesions. In conclusion, CMV disease occurring before engraftment in CMV-seropositive recipients was uncommon, was frequently associated with the presence of other opportunistic pathogens, and was associated with a high fatality rate. Better diagnostic methods to identify patients at risk are required in the preengraftment period.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9142777     DOI: 10.1093/clinids/24.5.830

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

1.  Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients.

Authors:  Filippo Milano; Steven A Pergam; Hu Xie; Wendy M Leisenring; Jonathan A Gutman; Ivy Riffkin; Victor Chow; Michael J Boeckh; Colleen Delaney
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

Review 2.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

3.  Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time PCR assay performed with blood plasma.

Authors:  Marianne Leruez-Ville; Marie Ouachée; Richard Delarue; Anne-Sophie Sauget; Stéphane Blanche; Agnès Buzyn; Christine Rouzioux
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

Review 4.  Quantitation of cytomegalovirus: methodologic aspects and clinical applications.

Authors:  M Boeckh; G Boivin
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

5.  Cytomegalovirus in Adult Allogeneic Blood and Marrow Transplant Patients Before or Around the Period of Neutrophil Recovery: A Single-Center, Retrospective, Descriptive Study.

Authors:  Isabella Martin; Alexandra Valsamakis; Douglas Gladstone; Richard Jones; Richard Ambinder; Robin K Avery
Journal:  Open Forum Infect Dis       Date:  2020-03-09       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.